<DOC>
	<DOCNO>NCT00848445</DOCNO>
	<brief_summary>To evaluate whether atrial fibrillation ( AF ) therapies Guidant Pulsar Max II Insignia Plus DR effect occurance AF patient prior history AF</brief_summary>
	<brief_title>Atrial Fibrillation : Canadian Atrial Fibrillation Evaluation ( CAFE ) Study -</brief_title>
	<detailed_description>This multi-centre , randomize , cross-over , prospective study evaluate occurrence AF AF pace therapy program ( APP VRR ) AF therapy program ( APP VRR ) patient know prior history AF ( patient pace indication ) . The occurrence AF well time first event AF burden ( frequecy duration ) .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>No prior history AF atrial flutter , primary indication SSS AV block dual chamber pacemaker , confidentiality agreement sign date implant , available followup study centre enrol protocol define interval , willing capable participate test associate study , stable regime arrhythmia management drug . Documented history AF atrial flutter , clinically significant ventricular arrhythmia , &lt; 18 yr old , life expectancy &lt; 1 year expectation heart transplantation study period , likely receive mechanical tricuspid valve study , enrol cardiovascular study , woman pregnant , inability refusal sign Patient Confidentiality Agreement , inability refusal complete followup schedule study centre enrol , exhibit arrhythmia due reversible cause eg , digitalis toxicity , hypoxia , transient electrolyte imbalance , acute myocardial infarction electrocution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>